[1]

West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006;94(11):1751–8.

doi: 10.1038/sj.bjc.6603127
[2]

Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2018;6:11–21.

doi: 10.2147/JHC.S159805
[3]

Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol. 2011;45(1):69–75.

doi: 10.1097/MCG.0b013e3181ce5dfa
[4]

Huang YH, Park BV, Chen YF, Gaba RC, Guzman G, Lokken RP. Locoregional therapy of hepatocellular-cholangiocarcinoma versus hepatocellular carcinoma: a propensity score-matched study. J Vasc Interv Radiol. 2019; 30(9):1317–24.

doi: 10.1016/j.jvir.2019.03.024
[5]

Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33(5):699–714.

doi: 10.1007/s12325-016-0324-7
[6]

Arslanoglu A, Seyal AR, Sodagari F, Sahin A, Miller FH, Salem R, et al. Current guidelines for the diagnosis and management of hepatocellular carcinoma: a comparative review. AJR Am J Roentgenol. 2016;207(5):W88–98.

doi: 10.2214/AJR.15.15490
[7]

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.

doi: 10.1055/s-0030-1247132
[8]

Randolph J, Falbe K, Manuel A, Balloun J. A step-by-step guide to propensity score matching in R. Pract Assess Res Eval. 2014;19:7.
[9]

Fowler K, Saad NE, Brunt E, Doyle MB, Amin M, Vachharajani N, et al. Biphenotypic primary liver carcinomas: assessing outcomes of hepatic directed therapy. Ann Surg Oncol. 2015;22(13):4130–7.

doi: 10.1245/s10434-015-4774-y